SOURCE: Atossa Genetics, Inc.

Atossa Genetics, Inc.

April 29, 2013 08:30 ET

Atossa Genetics to Exhibit at American Congress of Obstetrics and Gynecology Meeting

ForeCYTE Breast Health Test for Detection of Precancer and Cancer to Be Displayed

SEATTLE, WA--(Marketwired - Apr 29, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, will display its ForeCYTE Breast Health Test at the 61st Annual Clinical Meeting of the American Congress of Obstetrics and Gynecology in New Orleans from May 4 - 8, 2013. The Atossa exhibit will be located in booth #728 at the Ernest N. Morial Convention Center.

The ForeCYTE Breast Health Test, developed and marketed by Atossa Genetics, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses a hand-held, FDA Class II medical device that is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about the ForeCYTE Test, click here:

"As ForeCYTE testing can provide vital early detection of cancer or precancerous conditions and save lives by doing so, we look forward to personally presenting its value to the largest gathering of gynecologists, obstetricians, and related professionals in the nation," noted Chris Destro, Vice President of Atossa, who will attend the exhibition.

Mr. Destro added, "Our recent contracts with Multi-Plan and FedMed covering 97 million lives will help ensure access to our test within OB/GYN practices nationwide and ultimately help gain broader patient access."

Atossa's ForeCYTE Breast Health Test is available through physicians nationwide.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

In addition to the ForeCYTE Breast Health Test, Atossa markets the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

For additional information, please visit

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact Information

  • Contact:

    Atossa Genetics, Inc.
    Chris Destro
    Vice President
    (O) 800-351-3902
    (M) (206) 310-2335
    Email Contact

    Matthew D. Haines (Investors)
    Managing Director
    MBS Value Partners
    Email Contact